• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4173.TWO
Share

Arich Enterprise Co., Ltd. Stocks

NT$ 17.8Last Updated 24.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 40.79M

NT$ 17.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1969 and headquartered in New Taipei City, Taiwan, Arich Enterprise Co., Ltd. specializes in the marketing, promotion, and distribution of pharmaceutical products across Taiwan. Their portfolio includes both prescribed medications and over-the-counter drugs. Furthermore, the company extends its services to include a full suite of logistics operations for the pharmaceutical sector. These encompass inventory management for drug manufacturers, systematic distribution, handling of customer concerns, national transportation, and secure warehousing. Arich serves a diverse customer base, including hospitals, medical clinics, independent pharmacies, large retail drugstore chains, and hypermarkets.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, 'cheap'

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 02:12

Anthropic has introduced an affordable AI model for everyday tasks

25.07.2026 01:30

"FOMO Is Turning Into a Fear of Overinvesting": Nasdaq Lost More Than 2% Over the Week

25.07.2026 00:15

The YOLO strategy has backfired: traders' favorites are on track for their worst month in four years

24.07.2026 23:35

HSBC does not expect SpaceX's stock to rise. To value the stock, it had to abandon conventional methods.

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026